Shin Nippon Biomedical Laboratories Overview

  • Year Founded
  • 1957

Year Founded

  • Status
  • Public

  • Employees
  • 994

Employees

  • Stock Symbol
  • 2395

Stock Symbol

  • Investments
  • 21

  • Share Price
  • $6.96
  • (As of Friday Closing)

Shin Nippon Biomedical Laboratories General Information

Description

Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company's segment includes: CRO business (non-clinical business and clinical business), translational research business, Medipolis business, U.S. real estate business, and other businesses. The CRO business segment derives maximum revenue.

Contact Information

Website
www.snbl.com
Formerly Known As
Minami Nippon Dog Center, Shin Nippon Science
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 8-1 Akashi-cho, Chuo-ku
  • Saint Luke's Tower, 28th floor
  • Kagoshima, Kagoshima 104-0044
  • Japan
+81
Primary Industry
Drug Discovery
Stock Exchange
TKS
Corporate Office
  • 8-1 Akashi-cho, Chuo-ku
  • Saint Luke's Tower, 28th floor
  • Kagoshima, Kagoshima 104-0044
  • Japan
+81

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Shin Nippon Biomedical Laboratories Stock Performance

As of 20-Nov-2026, Shin Nippon Biomedical Laboratories’s stock price is $6.96. Its current market cap is $290M with 41.6M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$6.96 $7.20 $6.67 - $12.87 $290M 41.6M 308K $0.87

Shin Nippon Biomedical Laboratories Financials Summary

As of 30-Sep-2026, Shin Nippon Biomedical Laboratories has a trailing 12-month revenue of $224M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 31-Mar-2026 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024
EV 501,775 533,795 559,387 508,028
Revenue 224,460 215,790 212,552 183,061
EBITDA 73,239 64,587 57,245 60,867
Net Income 36,240 30,298 32,294 38,281
Total Assets 694,747 657,180 617,583 504,145
Total Debt 310,066 258,099 230,376 173,022
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Shin Nippon Biomedical Laboratories Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Shin Nippon Biomedical Laboratories‘s full profile, request access.

Request a free trial

Shin Nippon Biomedical Laboratories Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan.
Drug Discovery
Kagoshima, Japan
994 As of 2026

Tokyo, Japan
 

Osaka, Japan
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Shin Nippon Biomedical Laboratories Competitors (37)

One of Shin Nippon Biomedical Laboratories’s 37 competitors is CMIC CMO, a Private Equity-Backed company based in Tokyo, Japan.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CMIC CMO Private Equity-Backed Tokyo, Japan
Shionogi Corporation Osaka, Japan
Evotec Formerly PE-Backed Hamburg, Germany
Ipsen Formerly PE-Backed Paris, France
Vimta Labs Corporation Hyderabad, India
You’re viewing 5 of 37 competitors. Get the full list »

Shin Nippon Biomedical Laboratories Patents

Shin Nippon Biomedical Laboratories Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026164060-A1 Marker for cancer originating in pancreatic duct or precancerous lesion thereof Pending 28-Jan-2025
WO-2026126716-A1 Administration device Pending 11-Dec-2024
JP-2025041218-A Biomarker comprising limch1 Pending 13-Sep-2023
JP-2026521371-A Composition for improving mucosal penetration Pending 31-May-2023
AU-2024282997-A1 Compositions for enhanced mucosal penetration Pending 31-May-2023 A61K9/0043
To view Shin Nippon Biomedical Laboratories’s complete patent history, request access »

Shin Nippon Biomedical Laboratories Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Shin Nippon Biomedical Laboratories Investments & Acquisitions (21)

Shin Nippon Biomedical Laboratories’s most recent deal was a Later Stage VC with Cardio Intelligence for . The deal was made on 09-Mar-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Cardio Intelligence 09-Mar-2026 Later Stage VC Diagnostic Equipment
Hearvana 05-Nov-2025 Seed Round Software Development Applications
Tasso-SNBL 27-Mar-2025 Joint Venture Distributors/Wholesale
Kolmar BioTech 05-Dec-2024 PIPE Biotechnology
Shizen Connect 29-Nov-2024 Seed Round Business/Productivity Software
You’re viewing 5 of 21 investments and acquisitions. Get the full list »

Shin Nippon Biomedical Laboratories ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

19.61 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Laboratory Equipment and Services

Subindustry

of 67

Rank

Percentile

To view Shin Nippon Biomedical Laboratories’s complete esg history, request access »

Shin Nippon Biomedical Laboratories Exits (4)

Shin Nippon Biomedical Laboratories’s most recent exit was on 19-Aug-2021 from Life Log Technology. The exit was categorized as with 3 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Life Log Technology 19-Aug-2021 Completed
  • 3 buyers
WaVe Life Sciences 02-Feb-2015 Completed
  • 3 buyers
Agrivida 09-Nov-2006 Completed
  • 3 buyers
WaVe Life Sciences Corporate Completed
To view Shin Nippon Biomedical Laboratories’s complete exits history, request access »

Shin Nippon Biomedical Laboratories Affiliates

Subsidiaries (8)

Name Industry Location Year Founded
Tasso-SNBL Japan 2025
Gemseki Tokyo, Japan 2017
Trunk Solution Bunkyo-ku, Japan 2016
Satsuma Pharmaceuticals Durham, NC 2016
PPD SNBL Tokyo, Japan 2015
You’re viewing 5 of 8 affiliates. Get the full list.  »

Shin Nippon Biomedical Laboratories FAQs

  • When was Shin Nippon Biomedical Laboratories founded?

    Shin Nippon Biomedical Laboratories was founded in 1957.

  • Where is Shin Nippon Biomedical Laboratories headquartered?

    Shin Nippon Biomedical Laboratories is headquartered in Kagoshima, Japan.

  • What is the size of Shin Nippon Biomedical Laboratories?

    Shin Nippon Biomedical Laboratories has 994 total employees.

  • What industry is Shin Nippon Biomedical Laboratories in?

    Shin Nippon Biomedical Laboratories’s primary industry is Drug Discovery.

  • Is Shin Nippon Biomedical Laboratories a private or public company?

    Shin Nippon Biomedical Laboratories is a Public company.

  • What is Shin Nippon Biomedical Laboratories’s stock symbol?

    The ticker symbol for Shin Nippon Biomedical Laboratories is 2395.

  • What is the current stock price of Shin Nippon Biomedical Laboratories?

    As of 20-Nov-2026 the stock price of Shin Nippon Biomedical Laboratories is $6.96.

  • What is the current market cap of Shin Nippon Biomedical Laboratories?

    The current market capitalization of Shin Nippon Biomedical Laboratories is $290M.

  • What is Shin Nippon Biomedical Laboratories’s current revenue?

    The trailing twelve month revenue for Shin Nippon Biomedical Laboratories is $224M.

  • Who are Shin Nippon Biomedical Laboratories’s competitors?

    CMIC CMO, Shionogi, Evotec, Ipsen, and Vimta Labs are some of the 37 competitors of Shin Nippon Biomedical Laboratories.

  • What is Shin Nippon Biomedical Laboratories’s annual earnings per share (EPS)?

    Shin Nippon Biomedical Laboratories’s EPS for 12 months was $0.87.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process